

[0027] In some embodiments the antigen-binding molecule comprises:

[0028] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0029] HC-CDR1 having the amino acid sequence of SEQ ID NO:244

[0030] HC-CDR2 having the amino acid sequence of SEQ ID NO:34

[0031] HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and

[0032] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0033] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0034] LC-CDR2 having the amino acid sequence of SEQ ID NO:245

[0035] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0036] In some embodiments the antigen-binding molecule comprises:

[0037] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0038] HC-CDR1 having the amino acid sequence of SEQ ID NO:290

[0039] HC-CDR2 having the amino acid sequence of SEQ ID NO:291

[0040] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0041] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0042] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0043] LC-CDR2 having the amino acid sequence of SEQ ID NO:309

[0044] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0045] In some embodiments the antigen-binding molecule comprises:

[0046] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0047] HC-CDR1 having the amino acid sequence of SEQ ID NO:290

[0048] HC-CDR2 having the amino acid sequence of SEQ ID NO:291

[0049] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0050] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0051] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0052] LC-CDR2 having the amino acid sequence of SEQ ID NO:295 or SEQ ID NO:300

[0053] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0054] In some embodiments the antigen-binding molecule comprises:

[0055] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0056] HC-CDR1 having the amino acid sequence of SEQ ID NO:290

[0057] HC-CDR2 having the amino acid sequence of SEQ ID NO:291

[0058] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0059] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0060] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0061] LC-CDR2 having the amino acid sequence of SEQ ID NO:295

[0062] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0063] In some embodiments the antigen-binding molecule comprises:

[0064] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0065] HC-CDR1 having the amino acid sequence of SEQ ID NO:290

[0066] HC-CDR2 having the amino acid sequence of SEQ ID NO:291

[0067] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0068] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0069] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0070] LC-CDR2 having the amino acid sequence of SEQ ID NO:300

[0071] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0072] In some embodiments the antigen-binding molecule comprises:

[0073] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0074] HC-CDR1 having the amino acid sequence of SEQ ID NO:33

[0075] HC-CDR2 having the amino acid sequence of SEQ ID NO:277

[0076] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0077] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0078] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0079] LC-CDR2 having the amino acid sequence of SEQ ID NO:42

[0080] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.

[0081] In some embodiments the antigen-binding molecule comprises:

[0082] (i) a heavy chain variable (VH) region incorporating the following CDRs:

[0083] HC-CDR1 having the amino acid sequence of SEQ ID NO:33

[0084] HC-CDR2 having the amino acid sequence of SEQ ID NO:286

[0085] HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

[0086] (ii) a light chain variable (VL) region incorporating the following CDRs:

[0087] LC-CDR1 having the amino acid sequence of SEQ ID NO:41

[0088] LC-CDR2 having the amino acid sequence of SEQ ID NO:42

[0089] LC-CDR3 having the amino acid sequence of SEQ ID NO:43.